Form 4: Cytosorbents Director Jiny Kim's Equity Holdings Update

Cytosorbents Director Jiny Kim reported beneficial ownership of 77,819 common shares and was granted 22,000 stock options.

Summary

• Director Jiny Kim reported beneficial ownership of 77,819 shares of Cytosorbents Corporation common stock.
• This total includes 69,300 restricted stock units (RSUs) granted on April 1, 2022, which will be settled into shares of Common Stock upon vesting upon a "Change In Control" of the Company.
• The remaining 8,519 shares are directly owned common stock.
• Kim was granted 22,000 stock options on August 8, 2025, with an exercise price of $1, pursuant to the Company's 2014 Long-Term Incentive Plan.
• These stock options will vest in four equal quarterly installments over one year following the grant date, subject to continued service.
• The options expire on August 8, 2035.
• A Limited Power of Attorney was executed on August 8, 2025, appointing CFO Peter J. Mariani to handle Jiny Kim's Section 16(a) reporting obligations.

Sentiment

Score: 6

Explanation: The filing reports a routine equity grant to a director, which is a positive for aligning interests but does not indicate significant new financial performance or strategic shifts. The beneficial ownership of RSUs and common stock is also a stable indicator.

Positives

• The grant of 22,000 stock options to a director aligns their interests with shareholder value creation.
• The director's continued beneficial ownership, including RSUs and common stock, indicates ongoing commitment to the company.

Future Outlook

The vesting schedule for the granted stock options indicates future equity accumulation for the director over the next year, contingent on continued service.

Industry Context

This filing is a routine disclosure of insider equity holdings and compensation, common across all publicly traded companies. It reflects standard practices for aligning director incentives with company performance through equity grants.

Corporate Governance

Related Party Transactions

• Grant of 22,000 stock options to Director Jiny Kim, a related party, under the company's 2014 Long-Term Incentive Plan.
• Grant of 69,300 restricted stock units to Director Jiny Kim on April 1, 2022, vesting upon a change in control.

Stakeholder Impact

• Shareholders: The grant of stock options to a director aligns management incentives with shareholder interests, potentially leading to better long-term performance.
• Employees: The use of equity compensation plans (like the 2014 Long-Term Incentive Plan) can signal a commitment to performance-based rewards, potentially impacting employee morale and retention if similar plans are available to other key personnel.

Next Steps

• Vesting of 22,000 stock options in four equal quarterly installments over one year from August 8, 2025.
• Settlement of 69,300 restricted stock units upon a "Change In Control" of the Company.

Key Dates

Recommendation

This Form 4 filing details a routine equity grant to a director and their existing beneficial ownership. While the grant aligns director incentives with shareholder value, it does not provide new information regarding the company's operational performance, financial health, or strategic direction that would warrant a change in investment recommendation. It's a standard disclosure that provides transparency on insider holdings but lacks the depth for a strong buy or sell signal.

Keywords

Cytosorbents, CTSO, SEC Form 4, Insider Trading, Stock Options, Restricted Stock Units, Director Holdings, Equity Compensation, Corporate Governance